The Journal of Immunology, Vol 153, Issue 10 4418-4426, Copyright © 1994 by American Association of Immunologists

ARTICLES

Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells

JA Hedrick, Z Lao, SG Lipps, Y Wang, SC Todd, JD Lambris and CD Tsoukas
Department of Biology, San Diego State University, CA 92182.

EBV binds and infects HSB-2 T cells via a receptor distinct from CD21. To further study this novel EBV receptor, we expressed the first 470 amino acids of the EBV-gp350/220 using the baculovirus expression system. The recombinant gp350/220(1-470) has a m.w. of 95 kDa, reacts with anti-gp350/220 Abs, and binds CD21 in ELISA. Radiolabeled gp350/220(1-470) binds both HSB-2 and Raji cells. The gp350/220(1-470) protein also inhibits EBV binding to both HSB-2 and Raji, detected by flow cytometry. Lysates of HSB-2 cells compete with CD21 for binding to gp350/220(1-470), suggesting that the two receptors bind related epitopes on the recombinant protein. Scatchard analysis reveals that gp350/220(1-470) binds to 34,000 high affinity sites/HSB-2 cell (Kd = 0.92 x 10(-8) M) compared with the 97,000 high affinity sites bound/Raji cell (Kd = 1.78 x 10(-8) M). Utilizing a gp350/220(1-470)- affinity matrix, we identify a 70-kDa (55-kDa nonreduced) protein on the surfaces of 125I-labeled HSB-2 cells. Binding of this protein to the matrix is inhibited by anti-gp350/220 Ab 72A1. In summary, we characterize a novel EBV-binding molecule on HSB-2 cells, compare its reactivity with gp350/220 to that of CD21, and provide evidence of a gp350/220-reactive, 70-kDa protein on the surfaces of HSB-2 cells. In view of previous evidence of HSB-2 infectivity by EBV, we propose that the 70 kDa protein represents the novel EBV receptor.

This article has been cited by other articles:

				K. A. Young, X. S. Chen, V. M. Holers, and J. P. Hannan Isolating the Epstein-Barr Virus gp350/220 Binding Site on Complement Receptor Type 2 (CR2/CD21) J. Biol. Chem., December 14, 2007; 282(50): 36614 - 36625. [Abstract] [Full Text] [PDF]

				R. Asokan, J. Hua, K. A. Young, H. J. Gould, J. P. Hannan, D. M. Kraus, G. Szakonyi, G. J. Grundy, X. S. Chen, M. K. Crow, et al. Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN-{alpha}: A Potential Role in Systemic Lupus Erythematosus J. Immunol., July 1, 2006; 177(1): 383 - 394. [Abstract] [Full Text] [PDF]

				M. Urquiza, R. Lopez, H. Patino, J. E. Rosas, and M. E. Patarroyo Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells J. Biol. Chem., October 21, 2005; 280(42): 35598 - 35605. [Abstract] [Full Text] [PDF]

				J. M. Guthridge, K. Young, M. G. Gipson, M.-R. Sarrias, G. Szakonyi, X. S. Chen, A. Malaspina, E. Donoghue, J. A. James, J. D. Lambris, et al. Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface J. Immunol., November 15, 2001; 167(10): 5758 - 5766. [Abstract] [Full Text] [PDF]

				M. D’ADDARIO, A. AHMAD, J. W. XU, and J. MENEZES Epstein-Barr virus envelope glycoprotein gp350 induces NF-{kappa}B activation and IL-1{beta} synthesis in human monocytes-macrophages involving PKC and PI3-K FASEB J, December 1, 1999; 13(15): 2203 - 2213. [Abstract] [Full Text]

				J. E. Tanner and C. Alfieri Epstein-Barr Virus Induces Fas (CD95) in T Cells and Fas Ligand in B Cells Leading to T-Cell Apoptosis Blood, November 15, 1999; 94(10): 3439 - 3447. [Abstract] [Full Text] [PDF]

				B. Larochelle, L. Flamand, P. Gourde, D. Beauchamp, and J. Gosselin Epstein-Barr Virus Infects and Induces Apoptosis in Human Neutrophils Blood, July 1, 1998; 92(1): 291 - 299. [Abstract] [Full Text] [PDF]

				C. J. Roberge, S. R. McColl, B. Larochelle, and J. Gosselin Granulocyte-Macrophage Colony-Stimulating Factor Enhances EBV-Induced Synthesis of Chemotactic Factors in Human Neutrophils J. Immunol., March 1, 1998; 160(5): 2442 - 2448. [Abstract] [Full Text] [PDF]